Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Bioventures 2014 L.P. Mpm Sells 41,152 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 41,152 shares of the company’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $0.89, for a total transaction of $36,625.28. Following the transaction, the insider owned 5,321,436 shares of the company’s stock, valued at $4,736,078.04. This represents a 0.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Wednesday, November 19th, Bioventures 2014 L.P. Mpm sold 66,324 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $62,344.56.
• On Tuesday, November 18th, Bioventures 2014 L.P. Mpm sold 52,627 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total transaction of $48,943.11.
• On Monday, November 17th, Bioventures 2014 L.P. Mpm sold 57,061 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.95, for a total value of $54,207.95.
• On Friday, November 14th, Bioventures 2014 L.P. Mpm sold 61,640 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.93, for a total value of $57,325.20.
• On Thursday, November 13th, Bioventures 2014 L.P. Mpm sold 90,951 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $89,131.98.
• On Wednesday, November 12th, Bioventures 2014 L.P. Mpm sold 40,669 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total value of $44,329.21.
• On Tuesday, November 11th, Bioventures 2014 L.P. Mpm sold 55,810 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total value of $63,623.40.
• On Monday, November 10th, Bioventures 2014 L.P. Mpm sold 48,570 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.18, for a total value of $57,312.60.
• On Friday, November 7th, Bioventures 2014 L.P. Mpm sold 68,480 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.11, for a total transaction of $76,012.80.
• On Thursday, November 6th, Bioventures 2014 L.P. Mpm sold 54,452 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.21, for a total transaction of $65,886.92.

Werewolf Therapeutics Price Performance

Shares of NASDAQ:HOWL traded down $0.07 during midday trading on Thursday, hitting $0.85. The company’s stock had a trading volume of 465,207 shares, compared to its average volume of 732,451. The company has a market cap of $41.49 million, a P/E ratio of -0.53 and a beta of 0.72. Werewolf Therapeutics, Inc. has a 12-month low of $0.60 and a 12-month high of $2.38. The business’s 50 day simple moving average is $1.55 and its 200 day simple moving average is $1.33. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. On average, analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. boosted its holdings in Werewolf Therapeutics by 33.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after purchasing an additional 23,852 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Werewolf Therapeutics during the 1st quarter worth approximately $71,000. MPM Asset Management LLC boosted its holdings in shares of Werewolf Therapeutics by 0.6% in the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after buying an additional 25,688 shares in the last quarter. MPM Bioimpact LLC grew its position in shares of Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after buying an additional 20,799 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new stake in Werewolf Therapeutics during the 1st quarter worth $79,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on HOWL. Zacks Research raised shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 16th. Citigroup reaffirmed a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. JMP Securities cut their price target on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 21st. Bank of America lowered their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $7.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.